Benzinga·2025-10-29 11:54Group 1: Sempra - Sempra is recommended as a buy by Jim Cramer, supported by Wells Fargo analyst Shahriar Pourreza who initiated coverage with an Overweight rating and a price target of $115 [1] Group 2: Pfizer - Pfizer announced initial results from the HER2CLIMB-05 clinical trial for a new treatment for metastatic breast cancer (MBC) positive for HER2 [1] - Pfizer shares fell 1.1% to settle at $24.50 [6] Group 3: Dow Inc. - Dow reported a lower-than-expected third-quarter loss, with an adjusted loss of 19 cents per share, beating the projected 29-cent loss [2] - Revenue for Dow fell 8% year over year to $9.97 billion, missing the estimate of $10.23 billion [2] - Dow shares fell 1.4% to close at $25.38 [6] Group 4: Plug Power Inc. - Plug Power's stock fell over 20% after announcing a warrant inducement agreement to raise $370 million, raising concerns about shareholder dilution [3] - Plug Power shares dipped 5.7% to settle at $2.79 [6]